Cardiac Safety Research Resources & Toxicity Screening Tools

This page contains historical content and data sets originally hosted on the expired cardiac-safety.org domain. Selleckchem highly appreciates the consortium's significant contributions to global drug safety and regulatory science. To ensure these valuable scientific insights remain accessible to the research community, we have preserved and archived these records here.

Mission Statement: The Cardiac Safety Research Consortium (CSRC) legacy resources advance scientific knowledge on cardiac safety for new and existing medical products. By building a collaborative environment based upon the principles of the FDA Critical Path Initiative, this hub provides researchers with access to historical data, standardized definitions, and tools for conducting cardiac safety assessments.

View Our Impact & CSRC Achievements »

Emerging Insights in Drug-Induced Cardiotoxicity

Cardiovascular safety remains a critical bottleneck in the development of potent anti-tumor therapies. For instance, while Doxorubicin is a cornerstone in chemotherapy, its clinical utility is often limited by dose-dependent chronic cardiotoxicity and heart failure. Recent mechanistic studies emphasize that identifying a reliable Apoptosis related activator can help clarify the signaling pathways—such as DNA damage responses and oxidative stress—that lead to cardiomyocyte death. By integrating advanced hERG screening with cellular apoptosis assays, researchers can better predict the safety profile of novel compounds, ensuring that life-saving medications do not come at the cost of long-term cardiac health.

Key Research Initiatives

CiPA Potential Role in Drug Development Comprehensive In Vitro Proarrhythmia Assay initiatives and guidelines.
New Advances in CiPA Assessment Updates on drug-induced arrhythmias and in vitro assays.
Cardiovascular Safety in Oncology Clinical Trials Providing clarity for a new era of cancer therapeutics.
ECG Database Resources Access the ECG Data Warehouse for product development programs.
Standardized Definitions for Clinical Testing Draft definitions for testing and MI preamble.
Report on Endpoint Adjudication Official report regarding the use of endpoint adjudication in trials.

Regulatory Perspectives & Reports

Perspectives from Robert Temple (FDA) Insights on Rivaroxaban safety profiles and regulatory views.
Insights from Janet Woodcock (FDA) Discussion on drug safety and the Critical Path Initiative.
The Proarrhythmic Assessment of New Chemical Entities Workshop summary regarding new chemical entity assessment.
Early QT Assessment vs. Thorough QT Study Scientific update: Can routine clinical pharmacology studies replace TQT?
2016 CSRC Annual Report Annual summary of consortium activities and findings.

Cardiac Safety Research Resources & Toxicity Screening Tools

Emerging Insights in Drug-Induced Cardiotoxicity

Selleckchem Support for Safety & Efficacy Research

Key Research Initiatives

Regulatory Perspectives & Reports